Nal-IRI/FL is named as an intervention in 2 current clinical trials in our USA and Japan registers. 1 is recruiting patients now. The most common phase is Phase EARLY_PHASE1. The lead sponsor is SONIRE Therapeutics Inc. The most-studied condition is Pancreatic Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
NCT07033689 · ClinicalTrials.gov ↗ · Pancreatic Cancer
|
Phase EARLY_PHASE1 | Recruiting | SONIRE Therapeutics Inc | USA |
|
A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
NCT05601323 · ClinicalTrials.gov ↗ · Unresectable Pancreatic Cancer
|
Not applicable | Active, closed | SONIRE Therapeutics Inc | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| SONIRE Therapeutics Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Japan | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and Japan registers name Nal-IRI/FL as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is SONIRE Therapeutics Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nal-IRI/FL works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nal-IRI/FL works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nal-IRI/FL (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.